Prognostic value of the high-mobility group box-1 in young patients with chest pain

ARYA Atherosclerosis

Volumn 10, Issue 3, 2014, Pages 154-158

  Haghjooy Javanmard, Shaghayegh ^a   Sadeghi, Masoumeh ^b   Safavi, Shiva ^a   Gheraati, Maryam ^a   Dana, Nasim ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarkers; Coronary artery diseases; High mobility group box 1; Inflammation

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STENOSIS; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

EID: 84902310101     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wang W, Lee Y, Lee CH. Review: The physiological and computational approaches for atherosclerosis treatment. Int J Cardiol 2013; 167(5): 1664-1676.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
3. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol 2012; 28(6): 631-641.
4. Erlandsson HH, Andersson U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004; 34(6): 1503-1512.
5. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res 2013; 3(1): 1-20.
6. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11(12): 909-917.
7. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24(12): 2320-2325.
8. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16(3): 136-143.
9. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418(6894): 191-195.
10. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006; 20(14): 2565-2566.
11. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152(6): 1197-1206.
12. Sadeghi M, Pourmoghaddas M, Tavasoli A, Roohafza H. Is there any relationship between C-reactive protein level and complex coronary plaques in patients with unstable angina? ARYA Atheroscler 2010; 6(1): 31-34.
13. Davis K, Banerjee S, Friggeri A, Bell C, Abraham E, Zerfaoui M. Poly (ADP-ribosyl) ation of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis. Mol Med 2012; 18: 359-369.
14. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12(1): 56-62.
15. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11(12): 909-917.
16. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101(7): 2652-2660.
17. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254(4): 375-385.
18. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31(2): 313-319.
19. Yang J, Huang C, Yang J, Jiang H, Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2010; 345(1-2): 189-195.
20. Haraba R, Suica VI, Uyy E, Ivan L, Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 2011; 346(3): 361-368.
21. Biscetti F, Straface G, de Cristofaro R, Lancellotti S, Rizzo P, Arena V, et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59(6): 1496-1505.